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ABSTRACT
Antibiotic resistance is an extremely serious threat to the modern world. Since 2008, Gram-negative 
rods from the Enterobacteriaceae family gained the possibility of b-lactam degradation using NDM-1 
carbapenemase, encoded by the blaNDM gene. It often occurs in the genome of Klebsiella pneumoniae 
and can occur on both bacterial chromosome and plasmids. This creates a very high risk due to the 
widespread occurrence of bacteria from this family both in the environment and in human microflora. 
Lack of sensitivity to popular b-lactam antibiotics is especially dangerous for patients hospitalised for a 
long time with reduced immunity. In Poland, since 2011, the number of registered NDM+ isolates and 
related infections are constantly increasing, reaching 1780 cases in 2016. Bacilli showing the presence of 
the blaNDM gene are registered very often in the Mazowieckie and Podlaskie regions, while the number 
of such cases is the lowest in the Opolskie region. Inhibiting the growing number of infections caused by 
Enterobacteriaceae NDM+ is extremely difficult, and one of the methods to reduce this phenomenon is 
strict compliance with hygiene rules.
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Introduction
The phenomenon of antibiotic resistance is one of 
the biggest threats for public health in the modern world. 
It is a problem not only for the inhabitants of countries 
where hygiene rules are not respected, or for people with 
reduced immunity who have been hospitalised for a long 
time, but also for all those who may potentially have con-
tact with bacteria that is insensitive to antibiotics. A par-
ticularly dangerous example of such a microorganism 
is Klebsiella pneumoniae “New Delhi”, which produces 
metallo-b-lactamase rod from the Enterobacteriaceae 
family, the frequency of occurrence of which is constantly 
increasing in Poland and throughout the world.
Enterobacteriaceae family
The family of Gram-negative Enterobacteriace-
ae is an extremely diverse and very broad group of 
bacteria. They belong to the most common microor-
ganisms in nature such as: Enterobacter, Klebsiella, 
Escherichia, Shigella, Salmonella, Yersinia, Proteus, or 
Serratia. They include hundreds of species that live in 
water, soil, plants, and animals and are an extremely 
important element of human microflora. Most of them 
are not dangerous to people. Individual species, such 
as Yersinia pestis, are always pathogenic to humans, 
while others may cause opportunistic infections (e.g. 
Proteus mirabilis). The majority of bacilli belonging to 
this family, especially opportunistic, can move by cilia 
and are relative anaerobes. All of the Enterobacteria-
ceae members have the following common features: 
the ability to ferment glucose and reduce nitrates, and 
a lack of cytochrome oxidase and catalase production. 
An extremely important species of the rod that belongs 
to the mentioned family was discovered in the 19th 
century: Klebsiella pneumoniae. It is an element of 
the natural human microflora [1, 2]. It occurs in the 
oropharynx and rectum of people who are its carriers 
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[3, 4]. Klebsiella pneumoniae exists under anaerobic 
conditions, has the ability to ferment glucose and fruc-
tose, and on the MacConkey medium it grows in the 
form of a highly characteristic colonies, slightly pink, 
sometimes milky pink, reminiscent of morning dew 
drops, often with round, smooth shapes. Due to the 
very thick, mucous envelope, K. pneumoniae colonies 
have a slippery, moist surface [1, 2]. This envelope is 
also an important feature of virulence [1]. Bacteria from 
this species produce urease, enabling the breakdown of 
urea into ammonia, which facilitates the colonisation of 
the infected organism by limiting the function of the im-
mune system. K. pneumoniae is an extremely important 
aetiological factor in hospital infections. People treated 
with long-term antibiotic therapy are particularly vulnera-
ble to colonisation with this pathogen. Unfortunately, K. 
pneumoniae is acquiring resistance to new, commonly 
used groups of antibiotics and chemotherapeutics, 
which is a growing problem [3].
The phenomenon of antibiotic 
resistance
There are many definitions of antibiotic resistance 
as well as forms, causes, and consequences of this 
phenomenon. The simplest of them says that it is a con-
dition in which bacteria are not sensitive to the effects 
of an antibiotic, and it is caused by certain specific 
features of bacterium [2, 4, 5]. Incorrect behaviour of 
patients, doctors, farmers, cattlemen, and food indus-
try employees, resulting from ignorance or disregard 
of current recommendations, have contributed to the 
rapid increase in the importance of bacteria defence 
mechanisms against antibiotics. Antibiotic resistance 
of bacteria can be natural when insensitivity to a given 
antibiotic or a whole group is a constant characteristic 
for a species, e.g. due to the lack of a structure on which 
the antibiotic can act, or acquired nature, when the gene 
structures determining drug resistance are introduced 
into bacterial cells together with DNA by conjugation, 
transduction, or transformation [2, 4, 5]. The reservoir 
of genes determining antibiotic resistance are not only 
pathogenic bacteria, but also those harmless to hu-
mans, commonly found in the environment [5]. Bacteria 
showing resistance to antibiotics realise this feature 
using various mechanisms that neutralise the drug, 
e.g. prevention of drug penetration into the cell due to 
a thick cell wall, enzymatic degradation of the antibiotic, 
or its modification by adding new functional groups 
to its molecule, overproduction of the factor being an 
antibiotic placeholder, active removal of the drug with 
other toxins using efflux pumps, or such a change in 
metabolic pathways in the cell to replace that one on 
which the antibiotic acts [4, 5].
b-lactam antibiotics
b-lactam antibiotics are the most important and 
commonly used group of antimicrobial drugs. The key 
element of their structure, characteristic for all repre-
sentatives of this group of drugs, is the presence in 
their molecule of a four-element b-lactam ring, which 
determines their biological function. They show bac-
tericidal activity by the inhibition of the synthesis of 
peptidoglycan, which is an element that builds the cell 
wall in bacterial cells. This is possible due to the interac-
tion with penicillin-binding protein (PBP) involved in the 
final stage of cross-linking murein subunits in a process 
called transpeptidation. They are bactericidal against 
many Gram-positive bacteria, as well as some of the 
Gram-negative bacteria, including those belonging to 
the Enterobacteriaceae family. This is possible due to 
the activation of autolysis, disruption of the ion balance 
of Gram-negative bacteria, as well as stimulation of 
holin formation. There are five main groups of b-lactam 
antibiotics: penicillins, cephalosporins, cephamycins, 
carbapenems, and monobactams. Unfortunately, many 
mechanisms of resistance to b-lactams are known. 
These include the production by bacteria of enzymes 
that hydrolyse the binding in the b-lactam ring and 
thereby inactivation an antibiotic molecule, mutations 
within the PBP protein sequence – leading to changes 
in its structure, the formation of a completely new form 
of the PBP protein, not showing affinity for b-lactam 
antibiotics, and disruption of the transport (specific for 
Gram-negative bacteria) to the cell of the antibiotic by 
changing the amount and structure of porin proteins 
and the active removal of the drug from the bacterial 
cell [1, 6, 7]. 
Enzymatic degradation of antibiotics
Enzymatic degradation of the antibiotic, especially 
b-lactams (the basis of their construction is a b-lactam 
ring), is a very common defence mechanism for bacte-
ria. They have a characteristic enzyme that is necessary 
to exhibit biological activity, involving the inhibition of 
the synthesis of Gram-positive bacteria cell wall. A very 
large group of enzymes that inactivate b-lactam antibi-
otics are b-lactamases [8, 9]. b-lactamases that show 
activity towards only one type of antibiotics from this 
group are named penicillinases, cephalosporinases, 
or carbapenemases (the names indicate their most 
important substrates) [7]. Their simplest split by the 
mode of action includes: serine b-lactamases (SBL) 
and metallo-b-lactamases (MBL). The first of these 
groups is very large, and belonging enzymes causes 
the acylation and hydrolysis of the antibiotic using the 
active centre serine. On the other hand, metallo-b-lac-
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tamases in the active centre have a zinc cation, which 
enables b-lactam ring damage by the interaction with 
the antibiotic [8, 9, 10]. There are also other b-lactamase 
classification systems, e.g. the one proposed by Amber 
et al. This classification relies on analysis of the evo-
lutionary relationship of enzymes and distinguishing 
classes A, B, C, and D. Metallo b-lactamases, such as 
NDM (New Delhi metallo-b-lactamase), belong to class 
B [11, 12]. Class A includes such carbapenemases as 
KPC, GES, or MSP. Representatives of classes C and D 
are CMY and OXA carbapenemases, respectively [13]. 
Bush and Jacoby are the authors of a classification 
that assumes the split due to the speed of antibiotic 
degradation reactions and the potential sensitivity of 
enzymes to their inhibitors. This split includes groups I, 
II, III, and IV – metallo-b-lactamases belong to group III. 
Their most important common feature is the lack of any 
sensitivity to inhibitors, as well as high sensitivity to the 
presence of EDTA that binds metal cations [9, 14, 15]. 
With the application of b-lactams that are effective 
against Gram-negative bacteria, an increase in bacte-
rial infections showing the presence of acquired forms 
of b-lactamases has been observed. They are usually 
encoded on plasmids, and in cells they show consti-
tutive expression [8]. Within class B of b-lactamases, 
several key groups can be distinguished, which are 
acquired by bacteria. These are: b-lactamases with 
extended substrate spectrum, called ESBL, AmpC 
cephalosporinases, and carbapenemases. The first 
group provides the bacteria with a resistance to pen-
icillins, cephalosporins, and monobactams, while 
retaining sensitivity to cephamycins, carbapenems, 
and b-lactamase inhibitors. AmpC provides resistance 
to penicillins, cephalosporins of I-III generation, and 
monobactams. Carbapenems, considered to be exam-
ples of ‘last resort’ antibiotics, may be degraded by car-
bapenemases. Class B is their most important class. Its 
representatives are metallo-b-lactamases (MBL), which 
effectively hydrolyse all b-lactam antibiotics, including 
carbapenems, with the exception of monobactams [9]. 
Class B b-lactamases contain two zinc cations in the 
active site – the first cation is associated with three 
histidines, and the second one with the system of three 
amino acids: Cys-His-Asp [16]. They are the most active 
and therefore the most dangerous group of carbapen-
emases. They were first observed in representatives of 
the Pseudomonas aeruginosa species in the 1980s, and 
then in the 1990s in bacteria belonging to the Entero-
bacteriaceae family. The most important enzymes from 
the MBL group that a bacterial cell can acquire include 
IMP, VIM, and NDM [15]. Many groups of researchers 
are constantly conducting research aimed at obtaining 
effective NDM-1 metallo-b-lactamase inhibitors [17, 18]. 
Until recently, only inhibitors of serine b-lactamases, 
such as clavulanic acid, sulbactam, or tazobactam, 
which unfortunately showed no activity against MBL, 
were known. According to the research of Cahill et al., 
there are compounds that can inhibit both SBL and 
MBL activity. They are cyclic boroorganic compounds 
having in their structure a bond between carbon and 
boron [10]. Another NDM-1 carbapenemase inhibitor 
is the natural compound isolated from mould, Asper-
gillomarasmine A (AMA). According to the results from 
the studies of King et al., it restored bactericidal activity 
to antibiotics such as meropenem against members 
of the Enterobacteriaceae family, containing in their 
genome the blaNDM-1 gene [19]. There is also a group of 
compounds that are analogues of penicillins with a free 
thiol group, called bistiazolidines. They show a high 
ability to block NDM-1 b-lactamase activity, leading to 
inhibition of imipenem hydrolysis by enzymes produced 
by Escherichia coli NDM+ [20]. Attempts to overcome 
NDM+ strains using a combination of several currently 
known and used antibiotics are ongoing. Ojdana et 
al. showed that the combination of third generation of 
cephalosporin (ceftazidime), class A, B, and D b-lact-
amase inhibitor (avibactam) and an organophosphate 
compound (fosfomycin) shows high efficiency against 
K. pneumoniae NDM + [21]. Figure 1 shows a simplified 
classification scheme of acquired b-lactamases [9].
K. pneumoniae can show the presence of many 
mechanisms of resistance to antibiotics. Data published 
in 2015 by KORLD from the European network EARS-
Net, the aim of which was to control antibiotic resistance 
among bacteria in Europe, comprising several hundred 
tested isolates from about 60 hospitals, show that 100% 
of K. pneumoniae in Poland are resistant to aminopeni-
cillins. From the reported data, it follows that more than 
60% of the bacilli from this species are insensitive to 
fluoroquinolones and third-generation cephalosporins, 
and more than half to aminoglycosides. A very large 
proportion of the isolates turned out to be resistant to all 
three groups of drugs. Only 0.3% of all isolates showed 
resistance to carbapenemases [22]. 
 Genesis K. pneumoniae NDM-1
In 2008 the first person in the world to be diagnosed 
with infection of a bacteria strain (now called K. pneu-
moniae NDM-1) was a Swede of Indian origin. He was 
diagnosed in a hospital in New Delhi with a urinary tract 
infection. Bacteria isolated from his urine proved to be 
extremely resistant to ampicillin, cefoxitin, cefuroxime, 
ceftazidime, and piperacillin. They were sensitive only to 
colistin and tigecycline [23]. One of the reasons for the 
appearance of this form of antibiotic resistant bacteria 
was insufficient compliance in South Asia with the rules 
of hygiene and environmental pollution. Bacteria show-
ing the presence of NDM-1 carbapenemase also very 
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b-lactamases
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spectrum (ESBL)
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Cephalosporinases 
AmpC
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B class (metallo 
b-lactamases, MBL)
NDM 
VIM 
A class 
Figure 1. A simplified classification scheme of acquired b-lactamases [9]
often belong to the species E. coli and Enterobacter clo-
acae [24, 25]. A high risk of infection with bacteria show-
ing the ability to produce NDM-1 occurs in India and 
other regions of southern Asia [26]. The list of countries 
where the risk of infection is high, apart from such Asian 
countries as China or Japan, includes also many Eu-
ropean countries, such as: France, Belgium, the Neth-
erlands, Germany, Austria, Sweden, and Norway [27]. 
A difficult, and sometimes impossible to eradicate, in-
fection with K. pneumoniae NDM+ poses a number of 
threats with available medical devices. One of them is 
the possibility of infecting kidney transplant recipients, 
which has been documented by Karczewski et al. [28]. 
Genetic conditioning of the NDM 
resistance mechanism
The blaNDM gene is responsible for coding the 
NDM-1 enzyme [29]. It can be located both on the bac-
terial chromosome and on plasmids [27]. The second 
of these locations promotes horizontal gene transfer 
and the spread between bacteria of the gene encod-
ing the carbapenemase [27, 29]. The blaNDM gene has 
been located on plasmid types such as IncF [30, 31], 
IncA/C [30, 32], or IncL/M [33]. Particularly dangerous 
are cases are those in which, apart from the blaNDM 
gene, other genes that determine antibiotic resistance 
are also found on the plasmid. The results of this type 
of analysis were presented by Gamal et al., who from 
Egyptian patients isolates of K. pneumoniae isolated 
IncR plasmids containing both blaNDM and [34]. rmtF 
gene codes methyltransferase, which is responsible 
for modifying the aminoglycoside attachment site in 
16S rRNA bacterial ribosome. This leads to bacterial 
resistance to this group of antibiotics [35]. Data from 
Yan et al. show that in isolates obtained in China multi-
drug resistant K. pneumoniae were present, which apart 
from the blaNDM gene also had blaKPC-2 gene encoding 
carbapenemase belonging to class A according to 
Ambler and enzyme group 2 according to Bush and 
Jacoby [14, 36, 37]. Ho et al. from Hong Kong isolated 
and sequenced the pNDM-HK plasmid. It belongs to the 
group of IncL/M plasmids. It was observed that beyond 
to the gene responsible for the mechanism of resistance 
associated with NDM carbapenemase (blaNDM-1) it had 
other genes determining resistance to: b-lactams such 
as blaTEM-1 and blaDHA-1, aminoglycosides such as armA 
and aaaC2, macrolides such as mph2 and mel, and 
sulphonamides such as sul1 [38, 39].
Types of NDM metallo-b-lactamases
There are many different types of NDM metallo-b-lac-
tamases, depending on their structure. The differences 
between them in the primary structure of the protein 
are minimal, and they are caused by point mutations 
resulting in the exchange of one amino acid for another. 
The main type of NDM enzyme is NDM-1. This form of 
carbapenemase was discovered in 2008 in a Swedish 
patient in New Delhi, India [23]. It has a mass of about 
28 kDa and is made of 269 amino acids [13]. Subse-
quent variants of this enzyme, marked sequentially from 
2 to 17, are very rare. NDM-3, -4, -5, -6, -7, -8, -11, -12, 
-13, -15, and -17 were detected in E. coli, while NDM-9, 
-10, and -16 were detected in K. pneumoniae [29, 40]. 
Importantly, NDM metallo-b-lactamases (especially 
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NDM-1) are sometimes present in individual representa-
tives of Vibrionaceae and other non-Enterobacteriaceae 
species [41].
Carbapenemase-producing 
Enterobacteriaceae (CPE)
The Enterobacteriaceae family, which have the 
ability to produce carbapenemases, are called CPE 
(Carbapenemase-Producing Enterobacteriaceae). 
According to the KORLD definition, in order to confirm 
their presence in a patient, it is necessary to either 
obtain a positive Carba NP test (Nordmann-Poirel), 
or to determine the production of carbapenemase 
in a KORLD facility, or to obtain the confirmation of 
carbapenemase presence using genetic tests. The 
study may include, for example, the patient’s blood, 
an intraoperative segment taken from an infected 
wound, or bronchoscopy from a person diagnosed with 
pneumonia [42]. The mentioned Carba NP test is an 
extremely simple, cheap, and easy detection method, 
including bacilli from the Enterobacteriaceae family 
that produce carbapenemases [43]. For this group of 
bacteria, it has almost complete sensitivity and spec-
ificity compared to molecular methods [44]. This test 
involves the hydrolysis of imipenem by carbapenemas-
es derived from the lysate of a suspension of bacteria 
derived from a biological sample. The pH of the solution 
decreases due to the acidity of antibiotic breakdown 
products, which causes the red colour in the alkaline 
phenol solution to change to yellow [43, 44].   
CPE in Poland in the years 2011 to 2016
There is a very large reservoir of bacteria in Poland 
that can obtain the ability to produce carbapenemas-
es. This is due to the widespread occurrence of both 
E. coli and K. pneumoniae representatives. In the years 
2011 to 2016, as much as 98.8% of all bacteria in which 
the NDM-1 enzyme was detected belonged to the spe-
cies K. pneumoniae (Fig. 2). Approximately 1% of cases 
are representatives of the E. coli species. This means 
that every case of NDM+ strain in Poland is associated 
with the Enterobacteriaceae family [45]. In Poland, the 
first case of infection caused by a representative of 
the Enterobacteriaceae family producing New Delhi 
metallo-b-lactamase 1 (NDM) appeared in 2011 in the 
Mazowieckie region [46]. He was a middle-aged man 
transported by air to Warsaw from Congo, where he was 
admitted to hospital due to sudden cardiac arrest. In his 
urine, an E. coli bacterium was identified showing the 
presence of New Delhi metallo-b-lactamase 1. In spite 
of almost two weeks of colistin treatment, the patient 
died due to multi-organ failure [47]. In the following 
year, four cases of infection with bacteria showing 
the presence of NDM enzymes were registered in the 
Wielkopolska region. A huge increase in the number 
of observed infection cases, equal to 103, took place 
in 2013. The number of infections in 2014 was more 
than twice as high as in the previous year, and since 
2016 it has exceeded 1000 cases [46]. The KORLD 
data shows that, in the years between 2011 and 2016, 
2605 cases of NDM+ isolates were recorded [45, 46]. 
According to data published by Baraniak et al., many 
cases of NDM+ from the Enterobacteriaceae family 
occurring in Poland, especially in the early years of 
their occurrence (2012–2014), were acquired abroad. 
For example, three cases of infection from 2013 were 
reported in patients from Montenegro, Afghanistan, 
and India. Due to the fact that the species showing the 
presence of the blaNDM-1 gene was P. mirabilis, the case 
of infection of a person returning from Afghanistan was 
particularly interesting [48].
The vast majority of cases, about 93.3%, were 
identified in hospitals, hospices, and in the course 
of admitting patients to hospitals. Analysing the 
age of infected patients, it can be stated that about 
65% of them were people over 65 years of age, and 
under the age of 19 years the cases of isolation of 
NDM+ strains practically did not occur. Perhaps 
due to insufficient compliance with hygiene rules, 
observed more often in men than women, in the first 
mentioned group the number of infected was slightly 
higher [45]. From the data collected at the surgery 
department of the Medical University of Warsaw in 
2012–2014 and published by Milner et al., it appears 
that from 236 K. pneumoniae strains isolated from 
patients’ biological materials 14 isolates (6%) showed 
a mechanism of resistance to antibiotics associated 
with the NDM-1 enzyme. None of these isolates was 
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Figure 2. Number of registered cases of bacteria from the 
Enterobacteriaceae NDM-1 family from 2011 to 2016 [46, 49]
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Figure 3. Number of registered cases of bacteria from 
the Enterobacteriaceae NDM-1 family in 2016 from the 
Mazowieckie and Podlaskie regions, relative to others [46]
obtained in 2012, while as many as 11 of them were 
from 2013. All NDM+ was sensitive to gentamicin, but 
at the same time none of the isolates was sensitive 
to ertapenem. As many as 14% of isolates were not 
sensitive to colistin [3]. Nawfal Dagher et al. proved 
that registered in Lebanon, insensitive to colistin 
the K. pneumoniae isolate showed the presence of 
NDM-5 carbapenemase [50].
1780 cases of Enterobacteriaceae NDM-1 bacteria 
were registered in 2016. About 78% of these cases took 
place in the Mazowieckie region (Fig. 3). In 14 regions 
(Fig. 4), the number of cases of bacteria containing 
the NDM-1 enzyme did not exceed 120, and it was 
more than two-fold lower than in the Podlaskie region. 
In the Podkarpackie, Opolskie, and Lubuskie regions 
no cases of NDM carbapenemase occurred in micro-
organisms [46].
CPE in Poland in 2017
Figures 5 and 6 show the numbers of recorded cas-
es of bacteria from the Enterobacteriaceae NDM-1 family 
in the first three quarters registered in Mazowieckie, 
Podlaskie, and others (Fig. 5) and in regions outside 
Mazowieckie and Podlaskie (Fig. 6).
In 2017 about 2405 cases of NDM+ isolates were 
recorded – more than half were registered in the Ma-
zowieckie region (Fig. 5) [46]. The Opolskie, Podkar-
packie, and Lubuskie regions, similarly as in 2016, were 
the places of registration with the smallest number of 
NDM+ strains. Both in the first and second quarter of 
2017, the number of registered cases of infection was 
higher than in the third quarter (Fig. 6) [51]. In the first 
quarter of 2017 the information about infection was 
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Figure 4. The number of recorded cases of bacteria from the Enterobacteriaceae NDM-1 family in 2016 [46]
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registered in regions outside Mazowieckie and Podlaskie [51]
obtained as a result of screening tests more often than 
infection diagnosis [52]. All the data available for the 
Mazowieckie region, due to the very large number of 
samples, from the period after the second quarter of 
2017 can be considered undervalued, due to restrictions 
concerning the confirmation of the presence of carbap-
enemases in some K. pneumoniae strains producing 
metallo-b-lactamases [46, 51]. 
Another interesting KORLD report allows for a more 
accurate analysis of data on the number of NDM+ isolates 
from 2016 and 2017. In the first quarter of 2017, more 
cases of patients with Enterobacteriaceae, mainly K. pneu-
moniae, NDM+ were recorded than in the first quarter of 
2016 (about 150%), particularly in the Mazowieckie and 
Podlaskie regions. In the first of them, in both years, a car-
rying of bacteria than infection was observed in twice as 
many people. On the other hand, in the Podlaskie region 
in the first quarter of 2016 the number of patients infected 
and those who were carriers of bacteria was similar, and 
in the first quarter of 2017 the number of carriers became 
almost twice as high as those infected [52].
CPE in Poland after 2017
In 2018, probably due to the change in the pro-
cedures for obtaining and registering test results by 
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KORLD in the Mazowieckie region, the number of 
registered NDM-1 isolates was lower than in 2017 and 
equalled 2355 [46]. However, this does not mean 
a decrease in the risk of bacteria from the Enterobac-
teriaceae family that produce NDM-1 carbapenemase. 
Not counting the Mazowieckie region, the number of 
registered NDM+ isolates in 2016–2018 increases in 
almost every region [46]. Table 1 presents a summary of 
the numbers of reported occurrences of NDM + isolates 
from the four selected Polish regions.
The data from the Region Sanitary and Epidemi-
ological Station in Warsaw show that 23 outbreaks of 
nosocomial infections were reported in 2018, which 
were caused by K. pneumoniae with the ability to form 
metallo-b-lactamase. From these 23 outbreaks, seven 
recognized by KORLD were caused by bacteria-produc-
ing enzymes NDM-1. Apart from these cases, 51 trans-
missions of K. pneumoniae MBL-type colonisation took 
place [53].
Summary and conclusions
Bacteria belonging to the Enterobacteriaceae family, 
having the blaNDM gene in their genome, are a growing 
problem not only in Poland but also throughout the 
world. The spread of multiresistant strains whose genes 
determining antibiotic resistance are located on plas-
mids is particularly worrying. Therefore, it is necessary 
to constantly try to discover new substances that inhibit 
or eliminate the effects of carbapenemases, such as 
their inhibitors, and new substances with bactericidal 
activity. In stopping the spread of antibiotic-resistant 
faecal sticks, hygiene, frequent hand washing, strict 
compliance with sanitary standards, and the respon-
sibility of all who have contact with antibiotics are 
extremely important.
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